SCHEMBL2155251

SCHEMBL2155251

CCOCOc1ccc2c(c1)OCC(COC(C)=O)(COC(C)=O)C2=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.36
KDM4E B2RXH2 7/20 0.36
GAA P10253 5/20 0.36
HPGD P15428 5/20 0.36
CASP1 P29466 3/20 0.36
HSD17B10 Q99714 3/20 0.36
SLC5A2 P31639 2/20 0.36
PRKCA P17252 1/20 0.36
MAPK14 Q16539 1/20 0.35
PTPN1 P18031 5/20 0.34
GLA P06280 3/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 2/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2155281 0.84 MAPT (0.42) ALDH1A1KDM4EGAAHSD17B10PRKCA
SCHEMBL2155857 0.84 CYP3A4 (0.43) ALDH1A1KDM4EHPGDSMN1; SMN2MAPT
SCHEMBL2155246 0.83 TSHR (0.39) ALDH1A1KDM4EGAAHPGDCASP1
SCHEMBL2156103 0.79 PRKCA (0.39) ALDH1A1KDM4EGAAHSD17B10PRKCA
SCHEMBL4620365 0.78 MAOB (0.36) ALDH1A1HPGDSMN1; SMN2
SCHEMBL2156979 0.75 PRKCA (0.44) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL12395267 0.71 MAPT (0.46) ALDH1A1HSD17B10PRKCASMN1; SMN2MAPT
SCHEMBL2155276 0.69 MAPT (0.40) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL2156923 0.68 TSHR (0.39) ALDH1A1GAAPRKCASMN1; SMN2MAPT
SCHEMBL5854508 0.66 CYP19A1 (0.37) ALDH1A1KDM4EHPGDCASP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US claimed
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed
US-7973072-B2 Pain, eating disorders, neurodegenerative disorders, memory impairment; attention deficit syndrome, opioid tolerance, drug addiction; (4-oxothiochroman-3,3-diyl)bis(methylene)bis(3-(trifluoromethyl)benzoate for example GRUENENTHAL GMBH (DE) 2011-07-05 US disclosed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US disclosed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US disclosed
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production GRUENENTHAL GMBH (DE) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161352-A1 Substituted Benzo-Condensed Cycloheptanone Derivatives and the Use Thereof for Medicament Production BCKDK, SYMPK, DHPS ALDH1A1 1598/4885KDM4E 715/4885GAA 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.